vs
Side-by-side financial comparison of CUMBERLAND PHARMACEUTICALS INC (CPIX) and EVERSPIN TECHNOLOGIES INC. (MRAM). Click either name above to swap in a different company.
EVERSPIN TECHNOLOGIES INC. is the larger business by last-quarter revenue ($14.9M vs $13.7M, roughly 1.1× CUMBERLAND PHARMACEUTICALS INC). EVERSPIN TECHNOLOGIES INC. runs the higher net margin — -2.0% vs -10.3%, a 8.3% gap on every dollar of revenue. On growth, CUMBERLAND PHARMACEUTICALS INC posted the faster year-over-year revenue change (31.1% vs 13.2%). Over the past eight quarters, CUMBERLAND PHARMACEUTICALS INC's revenue compounded faster (26.9% CAGR vs 18.2%).
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded prescription medicines. Its core product portfolio covers acute care, gastroenterology, pain management and rare disease treatment, with its primary operating market being the United States, serving healthcare providers and patients in relevant care segments.
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
CPIX vs MRAM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $13.7M | $14.9M |
| Net Profit | $-1.4M | $-296.0K |
| Gross Margin | 83.6% | 52.7% |
| Operating Margin | -10.0% | 29.0% |
| Net Margin | -10.3% | -2.0% |
| Revenue YoY | 31.1% | 13.2% |
| Net Profit YoY | 25.8% | — |
| EPS (diluted) | $-0.09 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.9M | ||
| Q4 25 | $13.7M | $14.8M | ||
| Q3 25 | $8.3M | $14.1M | ||
| Q2 25 | $10.8M | $13.2M | ||
| Q1 25 | $11.7M | $13.1M | ||
| Q4 24 | $10.4M | $13.2M | ||
| Q3 24 | $9.1M | $12.1M | ||
| Q2 24 | $9.8M | $10.6M |
| Q1 26 | — | $-296.0K | ||
| Q4 25 | $-1.4M | $1.2M | ||
| Q3 25 | $-1.9M | $54.0K | ||
| Q2 25 | $-740.7K | $-670.0K | ||
| Q1 25 | $1.3M | $-1.2M | ||
| Q4 24 | $-1.9M | $1.2M | ||
| Q3 24 | $-1.5M | $2.3M | ||
| Q2 24 | $-1.1M | $-2.5M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 83.6% | 50.8% | ||
| Q3 25 | 88.1% | 51.3% | ||
| Q2 25 | 81.4% | 51.3% | ||
| Q1 25 | 87.8% | 51.4% | ||
| Q4 24 | 81.1% | 51.3% | ||
| Q3 24 | 85.4% | 49.2% | ||
| Q2 24 | 82.6% | 49.0% |
| Q1 26 | — | 29.0% | ||
| Q4 25 | -10.0% | -7.2% | ||
| Q3 25 | -23.7% | -11.0% | ||
| Q2 25 | -6.9% | -14.9% | ||
| Q1 25 | 11.0% | -14.7% | ||
| Q4 24 | -17.7% | -11.8% | ||
| Q3 24 | -18.6% | -17.5% | ||
| Q2 24 | -10.4% | -26.5% |
| Q1 26 | — | -2.0% | ||
| Q4 25 | -10.3% | 8.1% | ||
| Q3 25 | -23.4% | 0.4% | ||
| Q2 25 | -6.8% | -5.1% | ||
| Q1 25 | 10.7% | -8.9% | ||
| Q4 24 | -18.2% | 9.2% | ||
| Q3 24 | -17.0% | 18.8% | ||
| Q2 24 | -11.0% | -23.5% |
| Q1 26 | — | $-0.01 | ||
| Q4 25 | $-0.09 | $0.05 | ||
| Q3 25 | $-0.13 | $0.00 | ||
| Q2 25 | $-0.05 | $-0.03 | ||
| Q1 25 | $0.08 | $-0.05 | ||
| Q4 24 | $-0.13 | $0.07 | ||
| Q3 24 | $-0.11 | $0.10 | ||
| Q2 24 | $-0.08 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.4M | $40.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $24.9M | $70.2M |
| Total Assets | $76.8M | $83.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.5M | ||
| Q4 25 | $11.4M | $44.5M | ||
| Q3 25 | $15.2M | $45.3M | ||
| Q2 25 | $16.1M | $45.0M | ||
| Q1 25 | $15.1M | $42.2M | ||
| Q4 24 | $18.0M | $42.1M | ||
| Q3 24 | $17.5M | $39.6M | ||
| Q2 24 | $17.3M | $36.8M |
| Q1 26 | — | $70.2M | ||
| Q4 25 | $24.9M | $68.9M | ||
| Q3 25 | $26.1M | $65.8M | ||
| Q2 25 | $28.0M | $64.1M | ||
| Q1 25 | $28.7M | $63.0M | ||
| Q4 24 | $22.9M | $62.6M | ||
| Q3 24 | $24.8M | $59.3M | ||
| Q2 24 | $26.3M | $55.4M |
| Q1 26 | — | $83.2M | ||
| Q4 25 | $76.8M | $84.6M | ||
| Q3 25 | $65.9M | $80.3M | ||
| Q2 25 | $67.9M | $78.9M | ||
| Q1 25 | $69.9M | $80.2M | ||
| Q4 24 | $75.6M | $77.8M | ||
| Q3 24 | $76.7M | $72.6M | ||
| Q2 24 | $78.5M | $64.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.0K | $570.0K |
| Free Cash FlowOCF − Capex | $3.0K | — |
| FCF MarginFCF / Revenue | 0.0% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $4.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $570.0K | ||
| Q4 25 | $3.0K | $2.6M | ||
| Q3 25 | $187.2K | $881.0K | ||
| Q2 25 | $843.8K | $5.0M | ||
| Q1 25 | $3.9M | $1.4M | ||
| Q4 24 | $1.9M | $3.8M | ||
| Q3 24 | $475.5K | $2.8M | ||
| Q2 24 | $-855.7K | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | $3.0K | $-975.0K | ||
| Q3 25 | $163.4K | $543.0K | ||
| Q2 25 | $817.3K | $3.0M | ||
| Q1 25 | $3.9M | $527.0K | ||
| Q4 24 | $1.9M | $2.1M | ||
| Q3 24 | $460.1K | $2.8M | ||
| Q2 24 | $-862.8K | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | -6.6% | ||
| Q3 25 | 2.0% | 3.9% | ||
| Q2 25 | 7.5% | 22.9% | ||
| Q1 25 | 32.9% | 4.0% | ||
| Q4 24 | 18.2% | 15.8% | ||
| Q3 24 | 5.1% | 22.9% | ||
| Q2 24 | -8.8% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 24.3% | ||
| Q3 25 | 0.3% | 2.4% | ||
| Q2 25 | 0.2% | 15.1% | ||
| Q1 25 | 0.4% | 6.9% | ||
| Q4 24 | 0.0% | 13.2% | ||
| Q3 24 | 0.2% | 0.5% | ||
| Q2 24 | 0.1% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.19× | ||
| Q3 25 | — | 16.31× | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | — | 3.16× | ||
| Q3 24 | — | 1.25× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CPIX
Segment breakdown not available.
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
